One To Watch

Beacon Therapeutics

An ophthalmic gene therapy company with operations spanning the United Kingdom and the United States, with a corporate base in London and a U.S. presence in the Cambridge, Massachusetts area. The company develops retinal gene therapies intended for global clinical development.

Founding and History

Beacon Therapeutics was formed by Syncona through the combination of assets acquired with Applied Genetic Technologies Corporation and additional preclinical programs, including work originating from the University of Oxford. In July 2024, Beacon raised a 170 million dollar Series B financing. Around the same period, the company appointed Lance Baldo as chief executive officer and Thomas Biancardi as chief financial officer, with Dave Fellows moving to non-executive chair.

Therapy Areas and Focus

Beacon focuses on inherited and acquired retinal diseases. Its development priorities include X-linked retinitis pigmentosa and dry age-related macular degeneration, with additional programs aimed at genetically defined retinal disorders.

Technology Platforms and Modalities

Beacon develops adeno-associated virus gene therapies for retinal delivery. Its programs include subretinal gene replacement approaches for inherited retinal disease and intravitreal gene therapy concepts intended to broaden applicability in more prevalent retinal conditions.

Key Personnel

Lance Baldo is chief executive officer. Thomas Biancardi is chief financial officer. Daniel Chung is chief medical officer. Dave Fellows serves as non-executive chair.

Strategic Partnerships

Beacon’s formation and funding have been led by Syncona, with participation from venture investors including Forbion and Oxford Science Enterprises. The company’s lead inherited retinal program was licensed from the laboratory of Professor Robert MacLaren at the University of Oxford.

FAQ Section

Beacon develops retinal gene therapies using AAV vectors, with programs designed for delivery to ocular tissues to drive sustained expression of therapeutic proteins.

The company focuses on blinding retinal diseases, including inherited retinal degeneration and age-related retinal disease.

Laruparetigene zovaparvovec, also referred to as laru-zova or AGTC-501, is in Phase II/III development for X-linked retinitis pigmentosa. Beacon is also developing an intravitreal gene therapy program for dry age-related macular degeneration and a preclinical cone-rod dystrophy program targeting CDHR1.

In 2025, Beacon reported topline Phase II updates from its DAWN and SKYLINE studies of laru-zova in X-linked retinitis pigmentosa, including presentations at major retina meetings. In July 2024, the company announced a 170 million dollar Series B and, shortly after, appointed a new CEO and CFO.

Beacon has publicly reported interim and topline Phase II findings for laru-zova in X-linked retinitis pigmentosa from DAWN and SKYLINE, with outcomes presented in scientific forum settings.

Near-term milestones are driven by execution of the laru-zova program in X-linked retinitis pigmentosa as it progresses through Phase II/III development, alongside advancement of the intravitreal dry AMD program through earlier clinical entry activities.

Beacon is led by executives with backgrounds in ophthalmology drug development, gene therapy clinical execution, and biotech finance, with governance anchored by a Syncona-backed board structure established during the company’s 2023–2024 formation and financing.

Want to Update your Company's Profile?